DocumentsDate added
Original article
Zayneb A. Mohammed1*,Haydar F. Al-Tukmagi1,Hassan M. Abbas2
1 Clinical Pharmacy Department, College of Pharmacy, Baghdad University, Baghdad,Iraq
2 Clinical Pharmacy Department, Medical city, Baghdad, Iraq
Address reprint requests to:
*Dr. Zayneb A. Mohammed,
Clinical Pharmacy Department, College of Pharmacy,Baghdad University, Baghdad, Iraq. Tel: (+964) 7718493580
Article citation: Mohammed ZA,Al-Tukmagi HF, Abbas HM. The role of coenzyme Q10 in breast cancer.J Pharm Biomed Sci 2016;06(09):522–525.Available at www.jpbms.info
ABSTRACT
Oxidative stress plays a crucial role in pathogenesis as well as progression of all cancers including breast cancer. The aim of the present study was to explore the possible protective effects of coenzyme Q10, an antioxidant agent, on Doxorubicin induced cardiotoxicity in breast cancer patients, we also investigated the role of coenzyme Q10 on oxidative stress. Sixty-four women having histologically confirmed breast cancer participated in this study. The patients divided into two groups. Group (A) who treated with coenzyme Q10 supplement in addition to chemotherapy adriamycin plus cyclophosphamide (AC). Group (B) treated with chemotherapy only. In this study, serum coenzyme Q10, malondialdehyde (MDA), total antioxidant status (TAS), complete blood count (CBC), serum ALT, AST, creatine kinase (CK), renal functions (serum creatinine and urea), creatine phosphokinase (CPK), high sensitivity C-Reactive protein (hs-CRP) levels were determined. Ejection Fraction (EF) was determined by echocardiography for all participants at baseline as well as post treatment. Statistical analysis was performed using SPSS, version 23, USA for WINDOWS, results are defined as mean ± standard deviation SD. Serum coenzyme Q10, total antioxidant status (TAS) were low at baseline in both groups, serum malondialdehyde (MDA), high sensitivity C-reactive protein (hs-CRP) levels had decreased significantly after supplementation with coenzyme Q10. The reduction in EF was more pronounced in group B at the end of the work. The present study demonstrated that women with breast cancer have a low level of coenzyme Q10 as compared to those of healthy women. It also emphasizes the growing concern that oxidative damage may occur in those patients that exhaust the antioxidant defense of the body leading to a low levels of Coenzyme Q10 and TAS and increasing in inflammatory markers as well as oxidative stress markers which lead to cardiotoxicity. Administration of antioxidant supplements such as a coenzyme Q10 is necessary in women with breast cancer postoperative with adjuvant chemotherapy to minimizes its cardiotoxicity.
KEYWORDS breast cancer, coenzyme Q10, oxidative stress
REFERENCES
1.DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA a Cancer J Clin. 2014;64:52–62.
2.Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer:Epidemiology and Etiology. Cell Biochem Biophys. 2015;72:333–338.
3.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
4.Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther.2010;10:955–960.
5.Beral V, Reeves G, Bull D, Green J. Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103:296–305.
6.Thomas S. Cancer As a Metabolic Disease: On The Origin,Management, and Prevention of Cancer. John Wiley & Sons,2012.
7.Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–1642.
8.Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Progress in cardiovascular diseases. 2007;49(5):330–52.
9.Gönenç A, Ozkan Y, Torun M, Simşek B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J Clin Pharm Ther. 2001;26:141–144.
10.Czarnecka AM, Krawczyk T, Zdrożny M, Lubiński J, Arnold RS,Kukwa W, et al. Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. Breast cancer research and treatment. 2010;121(2):511–8.
11.Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J. 2007;401:1–11.
12.Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56.
13.Maria Zowczak-Drabarczyk M, Murawa D, Kaczmarek L, Połom K, Litwiniuk M. Total antioxidant status in plasma of breast cancer patients in relation to ERβ expression. Contemp Oncol (Pozn). 2013;17:499–503.
14.Gönenç A, Erten D, Aslan S, Akinci M, Simşek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int. 2006;30:376–380.
15.Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition. 2012;28:767–772.
16.Chai W, Cooney RV, Franke AA, Shvetsov YB, Caberto CP,Wilkens LR, et al. Plasma coenzyme Q10 levels and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Epidemiology Biomarkers & Prevention. 2010;19(9):2351–6.
17.Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ,Pella D, et al. Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2012:4;641–649.
18.Niklowitz P, Onur S, Fischer A, Laudes M, Palussen M, Menke F,et al. Coenzyme Q10 serum concentration and redox status in European adults: influence of age, sex, and lipoprotein concentration. J Clin Biochem Nutr. 2016;58:240–245.
19.Anna G, Toru T, Singh RB, Meester D, Wilson F, Douglas W, et al. New roles of coenzyme Q10 in cardiovascular diseases, discovered by a single group. World Heart J. 2013;5:159–171.
20.Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev. 2013;14:243–248.
21.Portakal O, Ozkaya O, Erden Inal M, Bozan B, Koşan M, Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clinical Biochem. 2000;33:279–284.
22.Kasapović J, Pejić S, Todorović A, Stojiljković V, Pajović SB. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct. 2008;26:723–730.
23.Shilpa HD, Anita R Bijoor. Malondialdehyde as a marker of lipid peroxidation in acute myocardial infarction patients. MRIMS journal of Health Sciences. 2013;1:20–22.
24.Del Pozo-Cruz J, Rodríguez-Bies E, Navas-Enamorado I, Del Pozo-Cruz B, Navas P, López-Lluch G. Relationship between functional capacity and body mass index with plasma coenzyme Q10 and oxidative damage in community-dwelling elderly people. Exp Gerontol. 2014;52:46–54.
25.Basu S, Harris H, Larsson A, Vasson MP, Wolk A. Is there any role for serum cathepsin S and CRP levels on prognostic information in breast cancer? The Swedish mammography cohort. Antioxid Redox Signal. 2015;23:1298–302.
26.Sara JD, Zhang M, Lennon R, Herrmann J, Lerman L, Lerman A. High sensitivity C-reactive protein is an independent marker of coronary endothelial dysfunction in patients with non obstructive coronary artery disease. J Am Coll Cardiol. 2016;67:360–360
27.Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72:333–338.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work. Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Anzar Ashraf1,Anita Chakravarti2,Priyamvada Roy2,Oves Siddiqui2,Shipra Goel2,Neeru Kapoor2,Premashish Kar3
1 Virology laboratory, Department of Microbiology, Maulana Azad Medical College, Delhi-110002, India
2 Department of Microbiology, Maulana Azad Medical College, Delhi-110002, India
3 Department of Medicine, Maulana Azad Medical College & Associated Lok Nayak Hospital, Delhi-110002, India
Address reprint requests to:
*Dr Anita Chakravarti,
Department of Microbiology, Maulana Azad Medical College, Delhi-110002, India
Article citation: Ashraf A, Chakravarti A,Roy P, Siddiqui O, Goel S, Kapoor N,Kar P. Revisiting the utility of biochemical profile in the diagnosis and management of hepatitis C virus infection: a study from India. J Pharm Biomed Sci 2016;06(09):502–507.
Abstract
Several serum analytes can be used for the management of liver diseases. The present study was carried out to assess the role of biochemical markers in the diagnosis and prognosis of HCV infection. Blood samples (5 ml) collected from 300 patients with chronic HCV infection were analyzed for the presence of HCV antibodies and HBsAg by ELISA, and the infection was reconfirmed using reverse transcription polymerase chain reaction (PCR). Genotyping was done by restriction fragment length polymorphism or direct sequencing. Quantitative detection of HCV RNA by real-time PCR and measurement of Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), Alkaline Phosphatase
(ALP), Bilirubin, Total Protein and Albumin levels was performed before and after 6 months of therapy. Anti HCV antibodies were found in 139 samples, of which 73 were positive for HCV RNA. Genotype 3 was the commonest genotype isolated, while an initial viral load of patients was higher in genotype 1. SGPT, SGOT and bilirubin levels were significantly deranged in HCV antibody positive patients while SGPT, SGOT, albumin and ALP were markedly raised in HCV RNA positive patients. Among 139 HCV AB-positive patients, all six parameters were found to be significantly deranged in HCV RNA positive patients compared to negative patients. Pre-therapy levels of SGPT, bilirubin and ALP were significantly higher than post-therapy levels. SGOT, SGPT and bilirubin are important diagnostic markers of HCV infection, while SGPT, bilirubin and ALP are valuable indicators of response to therapy. Biochemical profile can serve as cost-effective and dependable indirect marker for HCV infection.
KEYWORDS biochemical profile, diagnosis, hepatitis C virus infection, india, prognosis
REFERENCES
1.Penin F, Dubusson J, Rey FA, Moradpour D, Pawlotsky JM.Structural biology of hepatitis C virus. Hepatology. 2004;39(1):5–19.
2.Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology.2013;57(4):1333–1342.
3.Goodgame B, Shaheen NJ, Galanko J, El-Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003;98(11):2535–2542.
4.Mukhopadhyaya A. Hepatitis C in India. J Biosci. 2008;33(4):465–73.
5.Chakravarti A, Verma V. Prevalence of Hepatitis C and B viral markers in patients with chronic liver disease: A study of from north India. Indian J Med Microbiol. 2005;23(4):273–274.
6.Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India. 2006;19(4):203–217.
7.Rehan HS, Manak S, Yadav M, Chopra D, Wardhan N. Diversity of genotype and mode of spread of Hepatitis C virus in Northern India. Saudi J Gastroenterol. 2011;17(4):241–244.
8.Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol.2006;4(5):645–652.
9.Khaliq S, Latief N, Jahan S. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon- based treatment. Arch Virol. 2014;159(1):1–15.
10. Wolf PL. Biochemical diagnosis of liver disease. Indian J Clin Biochem. 1999;14(1):59–90.
11.Mellor J, Hawkins A, Simmonds P. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J Clin Microbiol. 1999;37(8):2525–2532.
12.Chinchai T, Labout J, Noppornpanth S, Theamboonlers A, Haagmans BL, Osterhaus AD, et al. Comparative study of different methods to genotype hepatitis C virus type 6 variants. J Virol Methods.2003;109(2):195–201.
13.Jindal N, Jindal M, Jilani N, Kar P. Seroprevalence of hepatitis C virus (HCV) in health care workers of a tertiary care centre in New Delhi. Indian J Med Res. 2006;123(2):179–180.
14.Verma V, Chakravarti A, Kar P. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India. Diagn Microbiol Infect Dis.2008;61(4):408–414.
15.Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36(2):91–133.
16.Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–858.
17.Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–567.
18.Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol. 2006;78(4):452–458.
19.Chakravarti A, Dogra G, Verma V, Parkash AS. Distribution pattern of HCV genotypes & its association with viral load. Indian J Med Res. 2011;133(3):326–331.
20.Sarrazin C, Berg T, Lee JH, Rüster B, Kronenberger B, Roth WK, et al. Mutations in the Protein Kinase–Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a are associated with treatment response. J Infect Dis. 2000;181:432–441.
21.Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
22.Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med Wkly. 2010;140:3–11.
23.Shakil AO, Conry-Cantilena C, Alter HJ. Volunteer blood donors with antibody to hepatitis C Study Group. Ann Intern Med. 1995;123(5):330–337.
24.Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. American Association for the Study of Liver Diseases. 2016. http://www. hcvguidelines.org/full-report/monitoring-patients-who-arestarting-hepatitis-c-treatment- are-treatment-or-have
25.Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type specific differences in geographic origin and disease. Hepatology. 1994;19:13–18.
26.Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different regions of Pakistan and their possible routes of transmission. BMC Infect Dis. 2008;8:69.
27.Interpreting HCV serology and PCR results in diagnostic HCV testing. Australasian Society for HIV Medicine. 2015.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Suseela Kumari Pamu*,Lavanya Kollapu
Department of Microbiology, Rangaraya Medical College, GGH Campus Kakinada, Andhrapradesh, India
Address reprint requests to:
*Dr. Suseela Kumari Pamu, Department of Microbiology, Rangaraya Medical College, GGH Campus, Kakinada, Andhrapradesh–533001, India
Article citation: Pamu SK, Kollapu L.Isolation of ß-haemolytic streptococci and grouping by enzymatic extraction.J Pharm Biomed Sci 2016;06(09):518–521.
Abstract
Streptococcus pyogenes (group A streptococcus) is one of the most common and ubiquitous human pathogen. It causes invasive and non-invasive human disease. The group A streptococcus infection can be further complicated by non-suppurative sequelae,
such as rheumatic fever, which usually follows throat infection and glomerulonephritis. A total number of 215 children screened for β-haemolytic streptococci from throat swabs and all culture positives are grouped by enzymatic extraction method and ASO estimation was done. All results were analysed statistically. Out of the 215 throat swabs 22.5% positive for β-haemolytic streptococci and grouped as group A 56.5% group C 31.1% group G 13.4%. All culture positives are sensitive to bacitracin 0.04 units and ASO estimated 54%. The proportion of antibiotic sensitivity was high for penicillin, vancomycin, cefotaxime and erythromycin, and the relative resistance to ampicillin and amoxicillin was seen. Our study suggests that the inappropriate use of antibiotic leads to drug resistance.
KEYWORDS β-haemolytic, streptococcal grouping, ASO, bacitracin sensitivity.
REFERENCES
1.Begovac J. Asymptomatic pharyngeal L carriage of beta-hemolytic streptococcus in J Croatia. Principle and practice of infectious disease. 3rd Edn., Churchill-Livingston Ltd. Philadelphia,1990;15–23.
2.Shet A, Kaplan E. Addressing the burden of group A streptococcal disease in India. Indian J Pediatr. 2004;71:41–48.
3.Carapetis JR. The current evidence for the burden of group A streptococcal diseases. World Health Organization 2005.Available at http://www.who.int/ child-adolescent health / New publications/CHILD_HEALTH/DP/WHO_FCH_CA_05.07pdf.
4.A text book of medical microbiology, Greenwood; Eighteenth edition 2012; part III Chapter 16: page no 187.
5.Menon T, Shanmugasundaram S, Kumar MP, Kumar CP. Group A streptococcal infections of the pharynx in a rural population in south India. Indian J Med Res. 2004;119(suppl):171–173.
6.Rammelkamp CH Jr. Epidemiology of Streptococcal infections.Harvey lect. 1957;51:113-142.
7.Bisno AL. Non-suppurative poststreptococcal sequelae: Rheumatic fever and glomerulonephritis. Vol. 2: Churchill Livingston Ltd. New York. N. Y. 1995.
8.Centor RM, Rvoff GE. Sore throat: streptococcal or not? Pediatr Care 1987;21:28–63.
9.Nandi S, Kumar R, Ray P, Vohra H, Ganguly NK. Group A streptococcal sore throat in a periurban population of Northern India: a one-year prospective study. Bull World Health Organ.2001;79:528–533.
10.Johnson DR, Kalpan E, Sramck J, Bicoava R, Havlicek J, Havalickova H, et al. Laboratory methods for the diagnosis of group A streptococcal infections: World Health Organization, Geneva, Switzerland; 1996.
11.Maxted WR. The use of bacitracin for identifying V J group A haemolytic streptococci. J Clin Pathol. 1953;6:224–226.
12.Levinson ML, Frank PF. Differentiation of group A from other beta hemolytic streptococci with bacitracin. J Bacteriol. 1955;69:284–287.
13.Edrerer GM, Hermann MM, Bruce R, Masten JM, Chapman SS. Rapid extraction method with pronase B for grouping beta hemolytic a streptococci. Appl Microboil. 1972;23:285–288.
14.Coleman DJ, McGhie D, Tebutt GM. Further studies on the reliability of the bacitarcin inhibition test for the presumptive identification of Lancefield Group A streptococci. J Clin Pathol.1977;30:421–426.
15.Pollock HM, Dahlgren BJ. Distribution of streptococcal groups in clinical specimens with evaluation of bacitracin screening. Appl Microbiol. 1974;27:141–143.
16.Waunmaker LW, Ayoub EM. Antibody titers in accute rheumatic fever. Circulation. 1960;21:598–614.
17.Ozturk CE, Yavuz T, Kaya D, Yucel M. The rate of asymptomatic throat carriage of group A streptococcus in school children and associated ASO titers in Duzce, Turkey. Jpn J Infect Dis.2004;57:271–272.
18.Navaneeth BV, Ray N, Chawda S, Selvarani P, Bhaskar M, Suganthi N. Prevelence of beta hemolytic streptococcus carrier rate among schoolchildren in Salem. Indian J Pediatr. 2001;68:985–986.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case Report
Nishi Tandon1, Neema Tiwari1, Nirupama Lal1,Vibhore Mahendru2
1Department of Pathology, Eras Lucknow Medical College and Hospital (ELMCH), Lucknow, India
2Department of Surgery, Eras Lucknow Medical College and Hospital (ELMCH), Lucknow, India
Address reprint request to:
*Dr. Neema Tiwari, Resident, Department of Pathology, Eras Lucknow Medical College and Hospital (ELMCH), Lucknow, India
Article citation: Tandon N, Tiwari N, Lal N, Mahendru V Inguinal Sarcoidosis – An Unusual Presentation Journal of Pharmaceutical and Biomedical Sciences. 2016; 06(09):534-536.
REFERENCES
1.Jim George, Reese Graves, Robert Meador. Inguinal lymphadenopathy as the initial presentation of sarcoidosis. Proc (Bayl Univ Med Cent). 2013;26(2):161–162.
2.Nathan MP, Pinsker R, Chase PH, Elguezabel A. Sarcoidosis presenting as lymphedema. Arch Dermatol. 1974;109(4):543–544.
3.Silver HM, Tsangaris NT, Eaton OM. Lymphedema and lymphography in sarcoidosis. Arch Intern Med. 1966;117(5):712–714.
4.Tedavi Edilen Sarkoidoz. Sarcoidosis presenting with inguinal lympadenopathy and treated with a combination of corticosteroids and aazothioprine. Turk J Rheumatol. 2012;27(3):212-213.
5.Chen ES, Moller DR; Medscape. Sarcoidosis-scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7:457-67. doi: 10.1038/nrrheum.2011.93.
6.Halil Yanardag, Metin Caner, Irfan Papila, Sedat Uygun, Sabriye Demirci, Tuncer Karayel. Diagnostic value of peripheral lymph node biopsy in sarcoidosis: A report of 67 cases. Can Respir J. 2007;4:209–211.
7.Newman LS, Rose CS, Maier LA. Sarcoidosis. New Engl J Med.1997;336:1226-–34. (Erratum in 1997;337:139).
8.James DG. Lymphoreticular involvement. In: James DG, ed. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel.Dekker, 1994:345–347.
9.Stirling RG, Cullinan P, Du Bois RM. Sarcoidosis. In: Schwarz M, King T, eds. Intestinal Lung Disease. Hamilton: BC Dekker Inc, 1988:279–323.
10.Muller- Quernheim J. Sarcoidosis: Immunopathogenic concepts and their clinical application. Eur Respir J. 1998;12:716–738.
11.Torrington KG, Shorr AF, Parker JW. Endobronchial disease and racial differences in pulmonary sarcoidosis. Chest. 1997;111:619–622.
12.DeRemee RA. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest. 1983;83:128–133.
Source of funding: None.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Majority of the information gathered are from media sources which don’t reflect the author’s own opinion.
Copyright © 2016 Tandon N, Tiwari N, Lal N, Mahendru V. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article
Mohamed1*, Tariq Abdul Razak2,Rosnani Hashim3
1 Kuliyyah of Pharmacy, International Islamic University Malaysia, Kuantan Campus, Kuantan, Pahang, Malaysia
2Director, International Islamic University Malaysia, Kuantan Campus, Kuantan,Pahang, Malaysia
3 Faculty of Pharmacy, Cyberjaya University College of Medical Sciences, Selangor,Malaysia
Address reprint requests to:
*Dr. Sahimi Mohamed,
Kuliyyah of Pharmacy, International Islamic University Malaysia, Kuantan Campus,25200 Kuantan, Pahang, Malaysia.
Tel: +6016 6661726,Fax: +609-5148442
Article citation: Mohamed S,Razak TA, Hashim R. Development of knowledge of anticoagulant questionnaire: a narrative literature review. J Pharm Biomed Sci 2016;06(09):526–533.Available at www.jpbms.info
ABSTRACT
Background In almost a decade, no new instrument has been developed to assess the knowledge of anticoagulant (KAC) since the validation of knowledge of anticoagulant questionnaire (KAC-Q). Therefore, this study aimed to develop a new instrument to measure KAC among the Malaysian population.
Methods The items for the new KAC-Q were developed based on the narrative literature review and focus group discussion. The Delphi Method was used to assess the content validity of the new KAC-Q. Fifteen experts were involved in three phases of the Delphi survey. The face validity was examined to ensure that the items in the questionnaire were understood by the targeted patients.
Results A total of 37 articles were found to be related to KAC. Almost 100 questions were compiled and categorized into nine domains. After three phases of the Delphi survey, 71 questions were deleted due to similar meaning, irrelevant and unsuitable to be used among the Malaysian population. Of the 29 questions retained, one question was deleted after the face validity test.
Conclusion The completeness and relevance of the KAC-Q as well as the meaning of each individual question were assessed through the content and face validity. With a good structured and adequate information, these 28 KAC-Q questions were considered to have good content and face validity. However, further psychometric testing is needed to ensure that KAC-Q is reliable and valid to aid health care providers in determining patients’ anticoagulant knowledge in targeted populations.
KEYWORDS anticoagulant, content validity, development, knowledge
REFERENCES
1.Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest J. 2012;141: suppl2:e152S–84S.
2.Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012;18:351–362.
3.Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence.2010;24:51–60.
4.Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645.
5.Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070–1074.
6.Nasser S, Mullan J, Bajorek B. Challenges of older patients’ knowledge about warfarin therapy. J Prim Care Community Health. 2012;3:65–74.
7.Matalqah LM, Radaideh KM, Sulaiman SAS, Hassali MA, Abdul Kader MAS. Relationship between patients’ warfarin knowledge and anticoagulation control: results of a validated tool in Malaysia. J Pharm Biomed Sci. 2013;30:967–974.
8.Van Damme S, Van Deyk K, Budts W, Verhamme P, Moons P.Patient knowledge of and adherence to oral anticoagulation therapy after mechanical heart-valve replacement for congenital or acquired valve defects. Hear Lung J Acute Crit Care.2011;40:139–146.
9.Farsalinos k, Trikilis I, Spyrou A, Savvopoulou M, Kostopoulou A,Livanis E, et al. Comparison of knowledge level about anticoagulation therapy between atrial fibrillation and prosthetic heart valve patients and its’ relation to INR goal attainment. J Am Coll Cardiol. 2012;59:E1701.
10.Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients ‘warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37:34–39.
11.Barcelona D, Marongiu F, Contu P. Patient education and oral anticoagulant therapy. Haematol J. 2002;87:1081–1086.
12.Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE,Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. Ann Pharmacother. 2013;47:714–724.
13.Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: The TREAT randomised trial. PLoS One. 2013;8:e74037.
14.Clark CM, Bayley EW. Evaluation of the use of programmed instruction for patients maintained on Warfarin therapy. Am J Public Health. 1972;62:1135–1139.
15.El-naby AGA, Hashem HY, Ismail GM. Evaluation of a designed warfarin educational program on patients ’ knowledge and incidence of side effects. Glob J Pharmacol. 2014;8:592–600.
16.Wong PY, Schulman S, Woodworth S, Holbrook A. Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis. J Thromb Haemost. 2013;11:491–502.
17.Deck ED. The effect of an educational intervention on oral anticoagulation therapy knowledge in primary care. [dissertation]. Evidence-based practice project reports. Paper 72. 2015.
18.Matalaqah LM, Radaideh K, Hassali MA. An instrument to measure anticoagulation knowledge among Malaysian community: A translation and validation study of the Oral Anticoagulation Knowledge (OAK) Test. Asian J Biomed Pharm Sci. 2013;3:30–37.
19.Baker JW, Pierce KL, Ryals CA. INR goal attainment and oral anticoagulation knowledge of patients enrolled in an anticoagulation clinic in a Veterans Affairs medical center. J Manag Care Pharm. 2011;17:133–142.
20.Wofford JL, Wells MD, Singh S. Best strategies for patient education about anticoagulation with warfarin: a systematic review. BMC Health Serv Res. 2008;8:40.
21.Zeolla MM, Brodeur MR, Dominelli A. Haines ST, Allie ND.Development and validation of an instrument to determine patient knowledge: the oral anticoagulation knowledge test. Ann Pharmacother. 2006;40:633–638.
22.Briggs AL, Jackson TR, Bruce S, Shapiro NL. The development and performance validation of a tool to assess patient anticoagulation knowledge. Res Social Adm Pharm. 2005;1:40–59.
23.Taylor FC, Ramsay ME, Tan G, Gabbay J, Cohen H. Evaluation of patients’ knowledge about anticoagulant treatment. Qual Heal Care. 1994;3:79–85.
24.Smith M. B, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, et al. Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology. 2010;116:61–69.
25.Yahaya AH, Hassali MA, Awaisu A, Shafie AA. Factors associated with warfarin therapy knowledge and anticoagulation control among patients attending a Warfarin Clinic in Malaysia. J Clin Diagnostic Res. 2009;3:1663–1670.
26.Lip GY, Lane DA, Ponsford J, Shelley A, Sirpal A. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110:354–358.
27.Nadar S, Begum N, Kaur B, Sandhu S, Lip GY. Patients’ understanding of anticoagulant therapy in a multiethnic population. J R Soc Med. 2003;96:175–179.
28.St-Louis L, Robichaud-Ekstrand S. Knowledge level and coping strategies according to coagulation levels in older persons with atrial fibrillation. Nurs Health Sci. 2003;5:67–75.
29.Rocha HT, Rabelo ER, Aliti G, de Souza EN. Knowledge of patients with mechanical valve prostheses concerning chronic oral anticoagulant therapy. Rev Lat Am Enfermagem.2010;18:696–702.
30.Janoly-Duménil A, Bourne C, Loiseau K, Luauté J, Sancho PO,Ciancia S, et al. Oral anticoagulant treatment - evaluating the knowledge of patients admitted in physical medicine and rehabilitation units. Ann Phys Rehabil Med. 2011;54:172–180.
31.Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res. 2014;133:550–554.
32.Rewiuk K, Bednarz S, Faryan P, Grodzicki T. Knowledge of antithrombotic prophylaxis among patients with atrial fibrillation. Cardiol J. 2007;14:44–49.
33.Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence,knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39:632–636.
34.Collins S, Barber A, Sahm LJ. Pharmacist’s counselling improves patient knowledge regarding warfarin, irrespective of health literacy level. J Pharm. 2014;2:114–123.
35.Voller H, Dovifat C, Glatz J, Körtke H, Taborski U, Wegscheider K. Self management of oral anticoagulation with the IN Ratio system: Impact of a structured teaching program on patient’s knowledge of medical background and procedures. Eur J Cardiovasc Prev Rehabil. 2004;11:442–447.
36.Hu A, Chow C, Dao D, Errett L, Keith M. Factors influencing patient knowledge of warfarin therapy after mechanical heart valve replacement. J Cardiovasc Nurs. 2006;21:169–175.
37.Hasan SS, Shamala R, Syed IA, Basariah N, Chong DW, Mei TK, et al. Factors affecting warfarin-related knowledge and INR control of patients attending physician- and pharmacist-managed anticoagulation clinics. J Pharm Pract. 2011;24:485–493.
38.Chenot JF, Hua TD, Abu Abed M, Schneider-Rudt H, Friede T,Schneider S, et al. Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care. BMC Fam Pract. 2014;15:104.
39.Khudair IF, Hanssens YI. Evaluation of patients’ knowledge on warfarin in outpatient anticoagulation clinics in a teaching hospital in Qatar. Saudi Med J . 2010;3:672–677.
40.Bounda GA, Ngarambe C, Ge WH, Yu F. Assessment and evaluation efficacy of a clinical pharmacist ‑ led inpatient warfarin knowledge education program and follow up at a Chinese tertiary referral teaching hospital. Arch Pharm Pract. 2013;4:168.
41.Fairbairn-Smith L, Cope W, Robinson B, Kamali F, Wynne H. Effect of provision of the NHSNPSA oral anticoagulant therapy patient information pack upon patients’ knowledge and anticoagulant control. J Thromb Haemost. 2011;9:231–233.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Acknowledgement: We gratefully acknowledge the Director General of Health, Malaysia for granting us the permission to publish this study and Hospital Tengku Ampuan Afzan (HTAA). We would also like to thank all the patients, expert panel members, pharmacists and other health care providers managing the W-MTAC at HTAA.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.